Use of Epothilone B (Patupilone) in Refractory Lymphoma and Advanced Solid Tumors in Dogs

Journal of Veterinary Internal Medicine

Volumn 27, Issue 1, 2013, Pages 120-125

  Meier, V ^a   Geigy, C ^a   Grosse, N ^a   McSheehy, P ^b   Rohrer Bley, C ^a  

^a UNIVERSITY OF ZURICH   (Switzerland)

^b NOVARTIS PHARMA AG   (Switzerland)

Author keywords

Chemotherapy; Epothilones; Microtubule stabilizing agents

Indexed keywords

ANTINEOPLASTIC AGENT; EPOTHILONE B; EPOTHILONE DERIVATIVE;

ANIMAL; ANIMAL DISEASE; ARTICLE; CELL LINE; CELL PROLIFERATION; CLINICAL TRIAL; DOG; DOG DISEASE; FEMALE; LYMPHOMA; MALE; NEOPLASM;

ANIMALS; ANTINEOPLASTIC AGENTS; CELL LINE; CELL PROLIFERATION; DOG DISEASES; DOGS; EPOTHILONES; FEMALE; LYMPHOMA; MALE; NEOPLASMS;

ANIMALIA; CANIS FAMILIARIS;

EID: 84872371687     PISSN: 08916640     EISSN: 19391676     Source Type: Journal    
DOI: 10.1111/jvim.12019     Document Type: Article

References (37)

1. Jordan M, Wilson L. Microtubules as a target for anticancer drugs. Nat Rev Cancer 2004;4:253-265.
2. Bollag D, McQueney P, Zhu J, et al. Epothilones, a new class of microtubule-stabilizing agents with a taxol-like mechanism of action. Cancer Res 1995;55:2325-2333.
3. Gradishar W. Management of advanced breast cancer with the epothilone B analog, ixabepilone. Drug Des Devel Ther 2009;3:163-171.
4. Bystricky B, Chau I. Patupilone in cancer treatment. Expert Opin Investig Drugs 2011;20:107-117.
5. Bocci G, Nicolaou K, Kerbel R. Protracted low-dose effects on human endothelial cell proliferation and survival in vitro reveal a selective antiangiogenic window for various chemotherapeutic drugs. Cancer Res 2002;62:6938-6943.
6. Woltering E, Lewis J, Maxwell P, et al. Development of a novel in vitro human tissue-based angiogenesis assay to evaluate the effect of antiangiogenic drugs. Ann Surg 2003;237:790-798; discussion 798-800.
7. Ferretti S, Allegrini P, O'Reilly T, et al. Patupilone induced vascular disruption in orthotopic rodent tumor models detected by magnetic resonance imaging and interstitial fluid pressure. Clin Cancer Res 2005;11:7773-7784.
8. Fogh S, Machtay M, Werner-Wasik M, et al. Phase I trial using patupilone (epothilone B) and concurrent radiotherapy for central nervous system malignancies. Int J Radiat Oncol Biol Phys 2010;77:1009-1016.
9. Freedman R, Bullitt E, Sun L, et al. A phase II study of sagopilone (ZK 219477; ZK-EPO) in patients with breast cancer and brain metastases. Clin Breast Cancer 2011;11:376-383.
10. Rustin G, Reed N, Jayson G, et al. A phase II trial evaluating two schedules of sagopilone (ZK-EPO), a novel epothilone, in patients with platinum-resistant ovarian cancer. Ann Oncol 2011;22:2411-2416.
11. Stupp R, Tosoni A, Bromberg J, et al. Sagopilone (ZK-EPO, ZK 219477) for recurrent glioblastoma. A phase II multicenter trial by the European organisation for research and treatment of cancer (EORTC) brain tumor group. Ann Oncol 2011;22:2144-2149.
12. Dumontet C, Jordan M. Microtubule-binding agents: A dynamic field of cancer therapeutics. Nat Rev Drug Discov 2010;9:790-803.
13. Momoi Y, Okai Y, Watari T, et al. Establishment and characterization of a canine T-lymphoblastoid cell line derived from malignant lymphoma. Vet Immunol Immunopathol 1997;59:11-20.
14. Fosmire S, Dickerson E, Scott A, et al. Canine malignant hemangiosarcoma as a model of primitive angiogenic endothelium. Lab Invest 2004;84:562-572.
15. Chretin J, Rassnick K, Shaw N, et al. Prophylactic trimethoprim-sulfadiazine during chemotherapy in dogs with lymphoma and osteosarcoma: A double-blind, placebo-controlled study. J Vet Intern Med 2007;21:141-148.
16. Le Tourneau C, Lee J, Siu L. Dose escalation methods in phase I cancer clinical trials. J Natl Cancer Inst 2009;101:708-720.
17. Vail D. Cancer clinical trials: Development and implementation. Vet Clin North Am Small Anim Pract 2007;37:1033-1057.
18. Vail D. Veterinary co-operative oncology group - common terminology criteria for adverse events (VCOG-CTCAE) following chemotherapy or biological antineoplastic therapy in dogs and cats v1.0. Vet Comp Oncol 2004;2:195-213.
19. Vail D, Michels G, Khanna C, et al. Response evaluation criteria for peripheral nodal lymphoma in dogs (v1.0)-a veterinary cooperative oncology group (VCOG) consensus document. Vet Comp Oncol 2010;8:28-37.
20. Eisenhauer E, Therasse P, Bogaerts J, et al. New response evaluation criteria in solid tumours: Revised RECIST guideline (version 1.1). Eur J Cancer 2009;45:228-247.
21. Crowley E, Callaghan R. Multidrug efflux pumps: Drug binding-gates or cavity? FEBS J 2010;277:530-539.
22. O'Reilly T, Wartmann M, Brueggen J, et al. Pharmacokinetic profile of the microtubule stabilizer patupilone in tumor-bearing rodents and comparison of anti-cancer activity with other MTS in vitro and in vivo. Cancer Chemother Pharmacol 2008;62:1045-1054.
23. Bley C, Jochum W, Orlowski K, et al. Role of the microenvironment for radiosensitization by patupilone. Clin Cancer Res 2009;15:1335-1342.
24. Edelman M. Novel taxane formulations and microtubule-binding agents in non-small-cell lung cancer. Clin Lung Cancer 2009;10(Suppl 1):S30-S34.
25. Poirier V, Hershey A, Burgess K, et al. Efficacy and toxicity of paclitaxel (taxol) for the treatment of canine malignant tumors. J Vet Intern Med 2004;18:219-222.
26. Simon D, Schoenrock D, Baumgartner W, Nolte I. Postoperative adjuvant treatment of invasive malignant mammary gland tumors in dogs with doxorubicin and docetaxel. J Vet Intern Med 2006;20:1184-1190.
27. Stalder M, Anthony C, Woltering E. Metronomic dosing enhances the anti-angiogenic effect of epothilone B. J Surg Res 2009;169:247-256.
28. Pasquier E, Honore S, Pourroy B, et al. Antiangiogenic concentrations of paclitaxel induce an increase in microtubule dynamics in endothelial cells but not in cancer cells. Cancer Res 2005;65:2433-2440.
29. Rubin E, Rothermel J, Tesfaye F, et al. Phase I dose-finding study of weekly single-agent patupilone in patients with advanced solid tumors. J Clin Oncol 2005;23:9120-9129.
30. Ten Bokkel Huinink W, Sufliarsky J, Smit W, et al. Safety and efficacy of patupilone in patients with advanced ovarian, primary fallopian, or primary peritoneal cancer: A phase I, open-label, dose-escalation study. J Clin Oncol 2009;27:3097-3103.
31. Kerbel R, Kamen B. The anti-angiogenic basis of metronomic chemotherapy. Nat Rev Cancer 2004;4:423-436.
32. Hofstetter B, Vuong V, Broggini-Tenzer A, et al. Patupilone acts as radiosensitizing agent in multidrug-resistant cancer cells in vitro and in vivo. Clin Cancer Res 2005;11:1588-1596.
33. Rohrer Bley C, Orlowski K, Furmanova P, et al. Regulation of VEGF-expression by patupilone and ionizing radiation in lung adenocarcinoma cells. Lung Cancer 2011;73:294-301.
34. Argyriou A, Marmiroli P, Cavaletti G, Kalofonos H. Epothilone-induced peripheral neuropathy: A review of current knowledge. J Pain Symptom Manage 2011;42:931-940.
35. Knapp D, Richardson R, Chan T, et al. Piroxicam therapy in 34 dogs with transitional cell carcinoma of the urinary bladder. J Vet Intern Med 1994;8:273-278.
36. Sorenmo K, Goldschmidt M, Shofer F, et al. Evaluation of cyclooxygenase-1 and cyclooxygenase-2 expression and the effect of cyclooxygenase inhibitors in canine prostatic carcinoma. Vet Comp Oncol 2004;2:13-23.
37. Fogh S, Machtay M, Werner-Wasik M, et al. Phase I trial using patupilone (epothilone B) and concurrent radiotherapy for central nervous system malignancies. Int J Radiat Oncol Biol Phys 2010;77:1009-1016.